Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: A model-based meta-analysis of placebo-controlled trials.

Obes Pillars · 2025 · PMC11840199 · PMID 39980735

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In comparison, although the GLP-1/GIP and GLP-1/GCG dual-agonists also showed a trend toward increased efficacy, their improvement was not as pronounced as that of the tri-agonists.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.